Product Information
FENOFIBRATE 67 MG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $0.0920 per EA under NDC 59651020101. Its NADAC has been published 204 times since Nov 9, 2022.
FDA first approved this application on Sep 20, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
67 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
59651020101
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA212232FDA Approved
9/20/2021
TE Code
AB
On Market Since
9/20/2021
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 67 MG CAPSULE has been published 204 times since Nov 9, 2022, and over the history we have for it it has declined 8.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0920 per EA |
|---|---|
| All-time high | $0.1152 (Aug 16, 2023) |
| All-time low | $0.0646 (Jun 19, 2024) |
| 52-week high | $0.0931 |
| 52-week low | $0.0783 |
| Median price | $0.0885 |
| Average price | $0.0896 |
| Largest weekly change | +38.2% (May 17, 2023) |
| Weeks tracked | 204 |
| Tracking since | Nov 9, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 67 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 67 MG CAPSULE, manufactured by Aurobindo Pharma Limited, is $0.0920 per EA (NDC 59651020101), effective Sep 30, 2026.
How has the price of FENOFIBRATE 67 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 67 MG CAPSULE has declined 8.8%. It has been tracked across 204 weekly CMS publications since Nov 9, 2022.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 67 MG CAPSULE?
Since Nov 9, 2022, the NADAC for FENOFIBRATE 67 MG CAPSULE has ranged from a low of $0.0646 (Jun 19, 2024) to a high of $0.1152 (Aug 16, 2023), with a median of $0.0885 per EA.
Are there cheaper alternatives to FENOFIBRATE 67 MG CAPSULE?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FENOFIBRATE 67 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures FENOFIBRATE 67 MG CAPSULE?
FENOFIBRATE 67 MG CAPSULE (NDC 59651020101) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.